Association of plasma xanthine oxidoreductase activity with severity and clinical outcome in patients with chronic heart failure

Otaki, Yoichiro; Watanabe, Tetsu; Kinoshita, Daisuke; Yokoyama, Masahiro; Takahashi, Toshio; Toshima, Taku; Sugai, Takayuki; Murase, Takayo; Nakamura, Takashi; Nishiyama, Satoshi; Takahashi, Hiroki; Arimoto, Takanori; Shishido, Tetsuro; Miyamoto, Takuya; Kubota, Isao

doi:10.1016/j.ijcard.2016.11.077

Cited by 75 publications

(86 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Otaki et al reported that both high and low XOR activity (≥ 120 and <33 pmol/100 µL/h), measured using a combination of [13C2, 15N2] xanthine and liquid chromatography/triple quadrupole mass spectrometry, was related to poor outcome in patients with chronic heart disease [22]. Although the pathological significance by which abnormal XOR activity is unclear, too low XOR activity might reflect impaired endothelial viability.…”

Section: Discussionmentioning

confidence: 99%

The Relationship between Xanthine Oxidoreductase and Xanthine Oxidase Activities in Plasma and Kidney Dysfunction

Terawaki¹,

Murase²,

Nakajima³

et al. 2017

J Clin Exp Nephrol

Self Cite

View full text Add to dashboard Cite

Background: Oxidative stress (OS) is thought to play a role in detrimental events among patients with chronic kidney disease (CKD). Although the mechanism of OS increases in CKD patients is unclear, it has been suggested that increased activity of xanthine oxidase (XO), the superoxideproducing form of xanthine oxidoreductase (XOR), plays a large role in enhancing OS. Therefore, we measured the activities of plasma XOR and XO among CKD patients.

show abstract

Section: Discussionmentioning

confidence: 99%

The Relationship between Xanthine Oxidoreductase and Xanthine Oxidase Activities in Plasma and Kidney Dysfunction

Terawaki¹,

Murase²,

Nakajima³

et al. 2017

J Clin Exp Nephrol

Self Cite

View full text Add to dashboard Cite

show abstract

“…On the other hand, an elevated SUA level on admission in patients with acute HF or ADHF associated not only with HF severity, but with the presence of chronic renal disease and the use of loop diuretics, which are able to cause negative clinical outcomes and independent predictor of 1-year mortality through elevation of SUA (Okazaki et al, 2017;Okazaki et al, 2016). Interestingly, the activity of xanthine oxidoreductase that is a key rate-limiting enzyme of purine degradation may be more accurate predictor of HFrEF severity and HF clinical outcomes than SUA (Otaki et al, 2017). Consequently, SUA remains a well-known risk factor of HF related clinical outcomes in acute HF and ADHF, while poor prognosis in patients with both phenotypes of chronic HF (HFrEF and HFpEF) is not elucidated.…”

Section: Serum Uric Acidmentioning

confidence: 99%

Up-to-date clinical approaches of biomarkers’ use in heart failure

Berezin¹

2017

Biomed. Res. Ther.

View full text Add to dashboard Cite

Heart failure (HF) is considered a leading cause of death in patients with established cardiovascular (CV) and metabolic diseases. Although current treatment strategy has improved survival rate and clinical outcomes of HF, the HF prevalence exhibits growth especially in older patients' population and survivors after coronary atherothrombotic events. Current clinical guidelines regarding treatment and prevention of HF claim the role of biological markers as pretty easy and powerful tool for diagnosis, risk stratification, and prognostication of HF. However, there is not clear whether all these biological markers are able to equally predict CV death and HF-related outcomes in patients with acute and chronic HF as well as in various phenotypes of HF. The aim of the review is to discuss a role of in risk stratification and individual treatment in patients with different phenotypes of HF.

show abstract

“…5 Reactive oxygen species (ROS), such as hydrogen peroxide (H 2 O 2 ) and superoxide anion (O 2 À ), are generated through the production of UA from xanthine, a reaction catalysed by XO. [9][10][11] In this study, we evaluated plasma XOR activity immediately after admission in patients with severely decompensated AHF patients requiring intensive care. Although the ratio of XDH to XO activity in the blood had not been sufficiently studied, 7 nowadays, the major hypothesis is that XDH is quickly converted to XO after being transferred to the bloodstream.…”

Section: Introductionmentioning

confidence: 99%

“…Recently, a strategy for measuring XOR levels was established, and several reports have been published regarding XOR levels observed in patients with chronic HF and cardiac disease and in normal volunteers. [9][10][11] In this study, we evaluated plasma XOR activity immediately after admission in patients with severely decompensated AHF patients requiring intensive care.…”

Section: Introductionmentioning

confidence: 99%

Plasma xanthine oxidoreductase activity in patients with decompensated acute heart failure requiring intensive care

et al. 2019

Self Cite

View full text Add to dashboard Cite

Aims Plasma xanthine oxidoreductase (XOR) activity during the acute phase of acute heart failure (AHF) requires further elucidation. Methods and results One hundred eighteen AHF patients and 231 control patients who attended a cardiovascular outpatient clinic were prospectively analysed. Blood samples were collected within 15 min of admission from AHF patients (AHF group) and control patients who visited a daily cardiovascular outpatient clinic (control group). Plasma XOR activity was compared between the two groups, and factors independently associated with extremely elevated XOR activity were identified using a multivariate logistic regression model. Plasma XOR activity in the AHF group (median, 104.0 pmol/h/mL; range, 25.9–423.5 pmol/h/mL) was significantly higher than that in the control group (median, 45.2 pmol/h/mL; range, 19.3–98.8 pmol/h/mL). The multivariate logistic regression model showed that serum uric acid (per 1.0 mg/dL increase, odds ratio: 1.280; 95% confidence interval: 1.066–1.536; P = 0.008) and lactate levels (per 1.0 mmol/L increase, odds ratio: 1.239; 95% confidence interval: 1.040–1.475; P = 0.016) were independently associated with high plasma XOR activity (>300 pg/h/mL) during the acute phase of AHF. Conclusions Plasma XOR activity was extremely high in patients with severely decompensated AHF. This would be associated with a high lactate value and would eventually lead to hyperuricaemia in patients with AHF.

show abstract

Association of plasma xanthine oxidoreductase activity with severity and clinical outcome in patients with chronic heart failure

Cited by 75 publications

References 24 publications

The Relationship between Xanthine Oxidoreductase and Xanthine Oxidase Activities in Plasma and Kidney Dysfunction

The Relationship between Xanthine Oxidoreductase and Xanthine Oxidase Activities in Plasma and Kidney Dysfunction

Up-to-date clinical approaches of biomarkers’ use in heart failure

Plasma xanthine oxidoreductase activity in patients with decompensated acute heart failure requiring intensive care

Contact Info

Product

Resources

About